Search

Your search keyword '"Kasner, Margaret"' showing total 343 results
Start Over Author "Kasner, Margaret"
343 results on '"Kasner, Margaret"'

7. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆

Author

Yee, Karen, Papayannidis, Cristina, Vey, Norbert, Dickinson, Michael J., Kelly, Kevin R., Assouline, Sarit, Kasner, Margaret, Seiter, Karen, Drummond, Mark W., Yoon, Sung-Soo, Lee, Je-Hwan, Blotner, Steven, Jukofsky, Lori, Pierceall, William E., Zhi, Jianguo, Simon, Silke, Higgins, Brian, Nichols, Gwen, Monnet, Annabelle, Muehlbauer, Susanne, Ott, Marion, Chen, Lin-Chi, and Martinelli, Giovanni

Published
2021
Full Text
View/download PDF

8. Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes

Author

Grosso, Dolores, Carabasi, Matthew, Filicko-O'Hara, Joanne, Wagner, John L., O'Hara, William, Sun, Michael, Colombe, Beth, Shi, W., Werner-Wasik, Maria, Rudolph, Shannon, Alpdogan, Onder, Binder, Adam, Kasner, Margaret, Klumpp, Thomas, Martinez-Outschoorn, Ubaldo, Palmisiano, Neil, Wilde, Lindsay, Porcu, Pierluigi, Gergis, Usama, and Flomenberg, Neal

Published
2020
Full Text
View/download PDF

10. A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

Author

Palmisiano, Neil, primary, Jeschke, Grace, additional, Wilde, Lindsay, additional, Alpdogan, Onder, additional, Carabasi, Matthew, additional, Filicko-O’Hara, Joanne, additional, Grosso, Dolores, additional, Klumpp, Thomas, additional, Martinez, Ubaldo, additional, Wagner, John, additional, Carroll, Martin P., additional, Perl, Alexander, additional, and Kasner, Margaret, additional

Published
2023
Full Text
View/download PDF

15. A Phase I Trial of Sirolimus with '7&3' Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

Author

Palmisiano, Neil, Jeschke, Grace, Wilde, Lindsay, Alpdogan, Onder, Carabasi, Matthew, Filicko-O'Hara, Joanne, Grosso, Dolores, Klumpp, Thomas, Martinez, Ubaldo, Wagner, John L, Carroll, Martin, Perl, Alexander, Kasner, Margaret, Palmisiano, Neil, Jeschke, Grace, Wilde, Lindsay, Alpdogan, Onder, Carabasi, Matthew, Filicko-O'Hara, Joanne, Grosso, Dolores, Klumpp, Thomas, Martinez, Ubaldo, Wagner, John L, Carroll, Martin, Perl, Alexander, and Kasner, Margaret

Abstract

Chemotherapy remains a primary treatment for younger AML patients, though many relapse. Data from our group have shown that highly phosphorylated S6 in blasts may predict response to sirolimus given with chemotherapy. We report the results of a phase I study of this combination in newly diagnosed AML and the pharmacodynamic analysis of pS6 before and after treatment. Subjects received sirolimus (12 mg on day 1, 4 mg daily, days 2-10), then idarubicin and cytarabine (days 4-10). Response was assessed at hematologic recovery or by day 42 using a modified IWG criteria. Fifty-five patients received sirolimus. Toxicity was similar to published 7 + 3 data, and 53% had high-, 27% intermediate-, and 20% favorable-risk disease. Forty-four percent of the high-risk patients entered into CR/CRp. Seventy-nine percent of the intermediate-risk subjects had a CR/CRp. All favorable-risk patients had a CR by day 42; 9/11 remained alive and in remission with a median follow-up of 660 days. Additionally, 41/55 patients had adequate samples for pharmacodynamic analysis. All patients demonstrated activation of S6 prior to therapy, in contrast to 67% seen in previous studies of relapsed AML. mTORC1 inhibition was observed in 66% of patients without enrichment among patients who achieved remission. We conclude that sirolimus and 7 + 3 is a well-tolerated and safe regimen. mTORC1 appears to be activated in almost all patients at diagnosis of AML. Inhibition of mTORC1 did not differ based on response, suggesting that AML cells may have redundant signaling pathways that regulate chemosensitivity in the presence of mTORC1 inhibition.

Published
2023

19. A Two-Step Approach to Myeloablative Haploidentical Transplantation: Low Nonrelapse Mortality and High Survival Confirmed in Patients with Earlier Stage Disease

Author

Grosso, Dolores, Gaballa, Sameh, Alpdogan, Onder, Carabasi, Matthew, Filicko-O’Hara, Joanne, Kasner, Margaret, Martinez-Outschoorn, Ubaldo, Wagner, John L., O'Hara, William, Rudolph, Shannon, Chervoneva, Inna, Colombe, Beth, Farley, Patricia Cornett, Flomenberg, Phyllis, Pro, Barbara, Sharma, Manish, Shi, Wenyin, Weiss, Mark, and Flomenberg, Neal

Published
2015
Full Text
View/download PDF

22. Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Author

Halloran, Molly, primary, Keiffer, Gina, additional, Giri, Veda, additional, Gross, Laura, additional, Wilde, Lindsay, additional, Palmisiano, Neil, additional, Porcu, Pierluigi, additional, and Kasner, Margaret, additional

Published
2022
Full Text
View/download PDF

28. Co-management Strategies for Acute Myeloid Leukemia Patients in the Community Setting

Author

Benton, Christopher, Grunwald, Michael R, Safah, Hana, Kasner, Margaret, Benton, Christopher, Grunwald, Michael R, Safah, Hana, and Kasner, Margaret

Abstract

The treatment landscape for acute myeloid leukemia (AML) has changed substantially in recent years. The introduction of newer therapies, including oral agents, less myelosuppressive agents, and parenteral regimens suitable for outpatient administration, has made it feasible for select patients to receive therapy in the outpatient setting and in community practices. Thorough patient evaluation (including molecular testing), planned supportive care (eg, transfusion support, antimicrobial prophylaxis), and vigilant patient monitoring (for tumor lysis syndrome and adverse events) by a multidisciplinary team are required for successful management of patients both in the community and at specialized leukemia centers. Some patients are unable or unwilling to travel to larger academic centers for treatment, and treatment of AML in the community setting may have potential advantages compared to less conveniently located academic/leukemia centers. This includes reduction of financial hardship for patients and their families and often better opportunities for family/caregiver support. Additionally, partnership between community practices and academic/leukemia centers is often crucial to optimizing AML management for many patients, as collaboration may facilitate access to additional expertise and trials, multidisciplinary teams for supportive care, easier transition to hematopoietic cell transplantation, and access to sophisticated molecular testing. In this review, we discuss AML treatment and management in the community setting, available therapies, and circumstances in which a referral to and co-management with an academic/leukemia center is more strongly recommended.

Published
2022

38. The diabetes gene Pdx1 regulates the transcriptional network of pancreatic endocrine progenitor cells in mice

Author

Oliver-Krasinski, Jennifer M., Kasner, Margaret T., Yang, Juxiang, Crutchlow, Michael F., Rustgi, Anil K., Kaestner, Klaus H., and Stoffers, Doris A.

Subjects
Mice -- Models, Mice -- Usage, Embryonic development -- Research, Embryonic development -- Physiological aspects, Embryonic development -- Genetic aspects, Diabetes -- Genetic aspects, Diabetes -- Control, Diabetes -- Research, Transcription factors -- Physiological aspects, Transcription factors -- Research
Abstract

Heterozygous mutations in the gene encoding the pancreatic homeodomain transcription factor pancreatic duodenal homeobox 1 (PDX1) are associated with maturity onset diabetes of the young, type 4 (MODY4) and type 2 diabetes. Pdx1 governs the early embryonic development of the pancreas and the later differentiation of the insulin-producing islet [beta] cells of the endocrine compartment. We derived a Pdx1 hypomorphic allele that reveals a role for Pdx1 in the specification of endocrine progenitors. Mice homozygous for this allele displayed a selective reduction in endocrine lineages associated with decreased numbers of endocrine progenitors and a marked reduction in levels of mRNA encoding the proendocrine transcription factor neurogenin 3 (Ngn3). During development, Pdx1 occupies an evolutionarily conserved enhancer region of Ngn3 and interacts with the transcription factor one cut homeobox 1 (Hnf6) to activate this enhancer. Furthermore, mRNA levels of all 4 members of the transcription factor network that regulates Ngn3 expression, SRY-box containing gene 9 (Sox9), Hnf6, Hnf1b, and forkhead box A2 (Foxa2), were decreased in homozygous mice. Pdx1 also occupied regulatory sequences in Foxa2 and Hnf1b. Thus, Pdx1 contributes to specification of endocrine progenitors both by regulating expression of Ngn3 directly and by participating in a cross-regulatory transcription factor network during early pancreas development. These results provide insights that may be applicable to [beta] cell replacement strategies involving the guided differentiation of ES cells or other progenitor cell types into the [beta] cell lineage, and they suggest a molecular mechanism whereby human PDX1 mutations cause diabetes., Introduction Insulin deficiency due to reduced pancreatic islet [beta] cell number underlies the progression of both type 1 and type 2 diabetes, prompting efforts to develop [beta] cell replacement therapies. [...]

Published
2009
Full Text
View/download PDF

39. Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience.

Author

Wilde, MD, Lindsay, Isidori, Alessandro, Keiffer, MD, Gina, Palmisiano, MD, Neil D., Kasner, Margaret, Wilde, MD, Lindsay, Isidori, Alessandro, Keiffer, MD, Gina, Palmisiano, MD, Neil D., and Kasner, Margaret

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent pandemic have impacted every aspect of oncology care worldwide. Healthcare systems have been forced to rapidly change practices in order to maximize the safety of patients and healthcare providers and preserve scare resources. Patients with acute myeloid leukemia are at increased risk of complications from SARS-CoV-2 not only due to immune compromise related to the malignancy but also due to the acuity of the disease and intensity of treatment. These issues have created unique challenges during this difficult time. In this article, we present the approaches taken by two groups of hematologist/oncologists, one in the United States and one in Italy, who have been caring for acute myeloid leukemia (AML) patients in the face of the pandemic.

Published
2020

45. Vaccination Response after Autologous Stem Cell Transplantation

Author

Alpdogan, Onder, primary, Hong, Jennifer, additional, Klumpp, Thomas R., additional, Abdulkareem, Abdullateef O, additional, Binder, Adam F., additional, Carabasi, Matthew, additional, Filicko-O'Hara, Joanne, additional, Grosso, Dolores, additional, Kasner, Margaret, additional, Martinez-Outschoorn, Ubaldo, additional, Palmisiano, Neil, additional, Wilde, Lindsay, additional, Porcu, Pierluigi, additional, Gergis, Usama, additional, Wagner, John L., additional, and Flomenberg, Neal, additional

Published
2020
Full Text
View/download PDF

46. COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Author

Wilde, Lindsay, primary, Binder, Adam F., additional, Carabasi, Matthew, additional, Filicko-O'Hara, Joanne, additional, Wagner, John L., additional, Alpdogan, Onder, additional, Kasner, Margaret, additional, Klumpp, Thomas R., additional, Martinez-Outschoorn, Ubaldo, additional, Palmisiano, Neil, additional, Keiffer, Gina, additional, Grosso, Dolores, additional, Millenson, Michael, additional, MacKenzie, Amy R., additional, Zibelli, Allison, additional, Flomenberg, Neal, additional, Porcu, Pierluigi, additional, and Gergis, Usama, additional

Published
2020
Full Text
View/download PDF

50. Integrating touchscreen-based geriatric assessment and frailty screening for adults with acute myelogenous leukemia to drive personalized treatment decisions.

Author

Wujcik, Debra, primary, Papadantonakis, Nikolaos, additional, Wall, Sarah Allison, additional, Kasner, Margaret T., additional, JAMY, OMER HASSAN, additional, Dudley, William, additional, Ingram, Stacey A., additional, Lawhon, Valerie, additional, Son, UI, additional, and Dudley, Matthew, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results